Advertisement

Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma

  • Hiroaki KajiyamaEmail author
  • Shiro Suzuki
  • Fumi Utsumi
  • Nobuhisa Yoshikawa
  • Kimihiro Nishino
  • Yoshiki Ikeda
  • Kaoru Niimi
  • Eiko Yamamoto
  • Michiyasu Kawai
  • Kiyosumi Shibata
  • Tetsuro Nagasaka
  • Fumitaka Kikkawa
Original Article
  • 35 Downloads

Abstract

Background

Occasionally, ovarian tumors are found to have originated from non-ovarian organs as metastatic lesions since the ovary is a common site of metastasis from many cancers. The aim of the current study was to estimate the long-term oncologic outcome of patients with metastatic mucinous ovarian carcinoma (MmOC) in comparison with those with primary mucinous ovarian carcinoma (PmOC) at an advanced stage.

Materials and methods

The data of one hundred and sixty-seven patients with mucinous ovarian cancer, including 91 patients with MmOC from the digestive organs and 76 patients with stage III–IV PmOC, were retrospectively analyzed. The prognostic significances of clinicopathologic factors were evaluated employing both uni- and multivariable analyses. Pathological slides were evaluated based on centralized pathological review.

Results

The median age of patients with PmOC and MmOC was 55 (18–81) and 51 years (30–82), respectively. With follow-up of a total of 167 patients, 145 patients (86.8%) developed recurrence. In addition, 122 patients (73.0%) died of the disease. Regardless of the residual tumor status, patients with PmOC did not a show a significantly poorer OS than those with MmOC. Furthermore, in a Cox multivariable hazard model, after adjustment for various clinicopathologic confounders, a gastric cancer (GC)-originated tumor and larger residual tumor were significant predictors of poorer OS [GC (vs. PmOC): HR (95% CI) 2.205 (1.303–3.654), P = 0.0036].

Conclusion

The oncologic outcome of patients with MmOC was extremely poor; however, it was almost the same as that of those with PmOC. We should recognize MmOC derived from gastric carcinoma as a highly aggressive malignancy.

Keywords

Metastatic ovarian carcinoma Mucinous epithelial ovarian carcinoma Overall survival Residual tumor Gastric carcinoma 

Abbreviations

PmOC

Primary mucinous ovarian carcinoma

MmOC

Metastatic mucinous ovarian carcinoma

WHO

World Health Organization

FIGO

International Federation of Gynecology and Obstetrics

OS

Overall survival

GC

Gastric carcinoma

CRC

Colorectal carcinoma

Notes

Acknowledgements

We sincerely thank all members of the Tokai Ovarian Tumor Study Group for collaborating in data collection.

Author contribution

HK: data analysis and interpretation, writing manuscript, SS, FU, YI, KN, KN, MK, and NY: data collection, TN: pathological evaluation, KS: supervisor of this work, FK: supervising and funding.

Funding

This study was supported by JSPS (Japan Society for the Promotion of Science) KAKENHI Grants-in-Aid for Scientific Research: Grant Numbers 17H04338 and 16K15704.

Compliance with ethical standards

Conflict of interests

The authors have nothing to disclose.

References

  1. 1.
    Brun JL, Feyler A, Chene G et al (2000) Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 78:21–27CrossRefGoogle Scholar
  2. 2.
    DiSilvestro P, Alvarez Secord A (2018) Maintenance treatment of recurrent ovarian cancer: is it ready for prime time? Cancer Treat Rev 69:53–65CrossRefGoogle Scholar
  3. 3.
    Kikkawa F, Nawa A, Ino K et al (2006) Advances in treatment of epithelial ovarian cancer. Nagoya J Med Sci 68:19–26Google Scholar
  4. 4.
    Perren TJ (2016) Mucinous epithelial ovarian carcinoma. Ann Oncol 27(Suppl 1):i53–i57CrossRefGoogle Scholar
  5. 5.
    Kajiyama H, Mizuno M, Shibata K et al (2014) Extremely poor postrecurrence oncological outcome for patients with recurrent mucinous ovarian cancer. Int J Clin Oncol. 19:121–126CrossRefGoogle Scholar
  6. 6.
    Schiavone MB, Herzog TJ, Lewin SN et al (2011) Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol 205(480):e1–e8Google Scholar
  7. 7.
    Hess V, A’Hern R, Nasiri N et al (2004) Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 22:1040–1044CrossRefGoogle Scholar
  8. 8.
    Zaino RJ, Brady MF, Lele SM et al (2011) Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer 117:554–562CrossRefGoogle Scholar
  9. 9.
    Pectasides D, Fountzilas G, Aravantinos G et al (2005) Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 97:436–441CrossRefGoogle Scholar
  10. 10.
    Shimada M, Kigawa J, Ohishi Y et al (2009) Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol 113:331–334CrossRefGoogle Scholar
  11. 11.
    Birnkrant A, Sampson J, Sugarbaker PH (1986) Ovarian metastasis from colorectal cancer. Dis Colon Rectum 29:767–771CrossRefGoogle Scholar
  12. 12.
    Cutait R, Lesser ML, Enker WE (1983) Prophylactic oophorectomy in surgery for large-bowel cancer. Dis Colon Rectum 26:6–11CrossRefGoogle Scholar
  13. 13.
    O’Brien PH, Newton BB, Metcalf JS et al (1981) Oophorectomy in women with carcinoma of the colon and rectum. Surg Gynecol Obstet 153:827–830Google Scholar
  14. 14.
    Kajiyama H, Suzuki S, Yoshikawa N et al (2019) Epidemiological overview of metastatic ovarian carcinoma ~ long-term experience of TOTSG database~. Nagoya J Med Sci 81(2) (in press)Google Scholar
  15. 15.
    Jiang R, Tang J, Cheng X et al (2009) Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors. Eur J Surg Oncol 35:92–97CrossRefGoogle Scholar
  16. 16.
    Jeung YJ, Ok HJ, Kim WG et al (2015) Krukenberg tumors of gastric origin versus colorectal origin. Obstet Gynecol Sci. 58:32–39CrossRefGoogle Scholar
  17. 17.
    Ji H, Isacson C, Seidman JD et al (2002) Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 21:391–400CrossRefGoogle Scholar
  18. 18.
    Seidman JD, Kurman RJ, Ronnett BM (2003) Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 27:985–993CrossRefGoogle Scholar
  19. 19.
    Vang R, Gown AM, Wu LS et al (2006) Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 19:1421–1428CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  • Hiroaki Kajiyama
    • 1
    Email author
  • Shiro Suzuki
    • 1
  • Fumi Utsumi
    • 2
  • Nobuhisa Yoshikawa
    • 1
  • Kimihiro Nishino
    • 1
  • Yoshiki Ikeda
    • 1
  • Kaoru Niimi
    • 1
  • Eiko Yamamoto
    • 1
    • 3
  • Michiyasu Kawai
    • 4
  • Kiyosumi Shibata
    • 2
  • Tetsuro Nagasaka
    • 5
  • Fumitaka Kikkawa
    • 1
  1. 1.Department of Obstetrics and GynecologyNagoya University Graduate School of MedicineNagoyaJapan
  2. 2.Department of Obstetrics and Gynecology, Bantane HospitalFujita Health UniversityNagoyaJapan
  3. 3.Department of Healthcare Administration, Graduate School of MedicineNagoya UniversityNagoyaJapan
  4. 4.Department of Obstetrics and GynecologyToyohashi Municipal HospitalToyohashiJapan
  5. 5.Department of Medical Technology, School of Health ScienceNagoya University Graduate School of MedicineNagoyaJapan

Personalised recommendations